|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Namikawa T and Hanazaki K:
Clinicopathological features and treatment outcomes of metastatic
tumors in the stomach. Surg Today. Jul 30–2013.(Epub ahead of
print).
|
|
3
|
He CZ and Zhang KH: Serum protein and
genetic tumor markers of gastric carcinoma. Asian Pac J Cancer
Prev. 14:3437–3442. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vey M, Schafer W, Berghofer S, Klenk HD
and Garten W: Maturation of the trans-Golgi network protease furin:
compartmentalization of propeptide removal, substrate cleavage, and
COOH-terminal truncation. J Cell Biol. 127:1829–1842. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson ED, VanSlyke JK, Thulin CD, Jean
F and Thomas G: Activation of the furin endoprotease is a
multiple-step process: requirements for acidification and internal
propeptide cleavage. EMBO J. 16:1508–1518. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Lartigue J, Polson H, Feldman M, et al:
PIKfyve regulation of endosome-linked pathways. Traffic.
10:883–893. 2009.PubMed/NCBI
|
|
7
|
Kappert K, Meyborg H, Fritzsche J, et al:
Proprotein convertase subtilisin/kexin type 3 promotes adipose
tissue-driven macrophage chemotaxis and is increased in obesity.
PLoS One. 8:e705422013. View Article : Google Scholar
|
|
8
|
Lopez de Cicco R, Bassi DE, Zucker S, et
al: Human carcinoma cell growth and invasiveness is impaired by the
propeptide of the ubiquitous proprotein convertase furin. Cancer
Res. 65:4162–4171. 2005.PubMed/NCBI
|
|
9
|
Komiyama T, Coppola JM, Larsen MJ, et al:
Inhibition of furin/proprotein convertase-catalyzed surface and
intracellular processing by small molecules. J Biol Chem.
284:15729–15738. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hilbig A: Src kinase and pancreatic
cancer. Recent Results Cancer Res. 177:179–185. 2008. View Article : Google Scholar
|
|
11
|
Okamoto W, Okamoto I, Yoshida T, et al:
Identification of c-Src as a potential therapeutic target for
gastric cancer and of MET activation as a cause of resistance to
c-Src inhibition. Mol Cancer Ther. 9:1188–1197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nam HJ, Im SA, Oh DY, et al: Antitumor
activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor,
alone or in combination with chemotherapeutic agents in gastric
cancer. Mol Cancer Ther. 12:16–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Summy JM and Gallick GE: Treatment for
advanced tumors: SRC reclaims center stage. Clin Cancer Res.
12:1398–1401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee M, Choy WC and Abid MR: Direct sensing
of endothelial oxidants by vascular endothelial growth factor
receptor-2 and c-Src. PLoS One. 6:e284542011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tekedereli I, Alpay SN, Tavares CD, et al:
Targeted silencing of elongation factor 2 kinase suppresses growth
and sensitizes tumors to doxorubicin in an orthotopic model of
breast cancer. PLoS One. 7:e411712012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Demidyuk IV, Shubin AV, Gasanov EV, et al:
Alterations in gene expression of proprotein convertases in human
lung cancer have a limited number of scenarios. PLoS One.
8:e557522013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Page RE, Klein-Szanto AJ, Litwin S, et al:
Increased expression of the pro-protein convertase furin predicts
decreased survival in ovarian cancer. Cell Oncol. 29:289–299.
2007.PubMed/NCBI
|
|
18
|
Thomas G: Furin at the cutting edge: from
protein traffic to embryogenesis and disease. Nat Rev Mol Cell
Biol. 3:753–766. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bassi DE, Mahloogi H, Lopez De Cicco R, et
al: Increased furin activity enhances the malignant phenotype of
human head and neck cancer cells. Am J Pathol. 162:439–447. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Strongin AY: Proteolytic and
non-proteolytic roles of membrane type-1 matrix metalloproteinase
in malignancy. Biochim Biophys Acta. 1803.133–141. 2010.PubMed/NCBI
|
|
21
|
Suboj P, Babykutty S, Valiyaparambil G,
Nair RS, Srinivas P and Gopala S: Aloe emodin inhibits colon cancer
cell migration/angiogenesis by downregulating MMP-2/9, RhoB and
VEGF via reduced DNA binding activity of NF-κB. Eur J Pharm Sci.
45:581–591. 2012.PubMed/NCBI
|
|
22
|
Stacker SA, Caesar C and Baldwin ME:
VEGF-D promotes the metastatic spread of tumor cells via the
lymphatics. Nat Med. 7:186–191. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tolde O, Rosel D, Mierke CT, et al:
Neoplastic progression of the human breast cancer cell line G3S1 is
associated with elevation of cytoskeletal dynamics and upregulation
of MT1-MMP. Int J Oncol. 36:833–839. 2010.PubMed/NCBI
|
|
24
|
Iravani O, Tay BW, Chua PJ, Yip GW and Bay
BH: Claudins and gastric carcinogenesis. Exp Biol Med (Maywood).
238:344–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zucker S, Pei D, Cao J and Lopez-Otin C:
Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev
Biol. 54:1–74. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakanishi Y, Ohara M, Domen H, Shichinohe
T, Hirano S and Ishizaka M: Differences in risk factors between
patterns of recurrence in patients after curative resection for
advanced gastric carcinoma. World J Surg Oncol. 11:982013.
View Article : Google Scholar
|
|
27
|
Parker MW, Hellman LM, Xu P, et al: Furin
processing of semaphorin 3F determines its anti-angiogenic activity
by regulating direct binding and competition for neuropilin.
Biochemistry. 49:4068–4075. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stawowy P, Blaschke F and Kilimnik A:
Proprotein convertase PC5 regulation by PDGF-BB involves
PI3-kinase/p70s6-kinase activation in vascular smooth
muscle cells. Hypertension. 39:399–406. 2002. View Article : Google Scholar : PubMed/NCBI
|
